Authorities are investigating after several people came down with symptoms of norovirus, the highly-contagious, ...

Vaxart Inc., in collaboration with researchers from multiple academic institutions, evaluated the VXA-G1.1-NN vaccine against ...

The Phase 2b trial is a double-blind, multi-center, randomized, comparator-controlled study. It is designed to evaluate the relative efficacy, safety, and immunogenicity of Vaxart's oral COVID-19 ...

Covid vaccine manufacturer Moderna has completed a new site in the UK, which it says will help prepare the the country ...

Vaxart's oral norovirus vaccine shows promise in mid-stage trials, reducing infections by 30%. Read more here.

Mr. Grasman brings over two decades of biotech financial leadership experience - SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the appointme ...

Vaxart Inc (VXRT) reports significant revenue growth and clinical advancements, despite facing operational hurdles and NASDAQ ...

Discover key insights from Vaxart's Q1 2025 earnings call, including progress on COVID-19 trials, norovirus pipeline updates, funding strategies, and ...

Actively screening for the 10,000 participant portion of COVID-19 Phase 2b trial; Dosing expected to begin in second quarter of 2025 Completed enrollment of Phase 1 clinical trial evaluating Company’s ...

Mr. Grasman brings over two decades of biotech financial leadership experience - SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the ...

Although the reasons for the lower efficacy are not fully clear, they mirror what has been seen with other live oral vaccines ...

HilleVax, Inc ( ($HLVX) ) has released its Q1 earnings. Here is a breakdown of the information HilleVax, Inc presented to its investors. HilleVax, ...